{"disease":{"id":"hepatocellular-carcinoma","name":"Hepatocellular Carcinoma","therapeutic_area":"Oncology","data":{"aiSummary":"The treatment landscape for HCC has evolved significantly with the advent of systemic therapies. Atezolizumab in combination with bevacizumab is a preferred first-line treatment option, along with lenvatinib. Sorafenib remains an option in later lines. The pipeline includes ongoing trials evaluating novel combinations and targeted therapies, with the goal of improving survival outcomes and expanding treatment options for patients with HCC.","drug_count":4,"description":"Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, often arising in the setting of chronic liver disease. The development of HCC is a complex process involving genetic and epigenetic alterations, as well as environmental factors. The prognosis for HCC varies widely depending on the stage at diagnosis and the patient\\","subtype_count":10},"enrichment_level":2,"last_enriched_at":null,"visit_count":0,"created_at":"2026-03-25T12:16:34.934Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"chembl-chembl1789844","indication_name":"First-Line Unresectable or Metastatic Hepatocellular Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1789844","indication_name":"Previously Treated Unresectable or Metastatic Hepatocellular Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1946170","indication_name":"Hepatocellular Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"REGORAFENIB","company_name":"","drug_phase":"marketed","molecular_target":"RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAF V600E, SAPK2, PTK5, Abl, CSF1R","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Regorafenib inhibits multiple kinases involved in oncogenesis, angiogenesis, metastasis, and tumor immunity."},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic hepatocellular carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of hepatocellular carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"anti-ox40-antibody-pf-04518600","indication_name":"Hepatocellular carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Anti-OX40 Antibody PF-04518600","generic_name":"anti-ox40-antibody-pf-04518600","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"OX40 receptor","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"pd-0332991","indication_name":"Advanced Hepatocellular Carcinoma","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PD-0332991","generic_name":"pd-0332991","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha, Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, Serine/threonine-protein kinase TAO2","drug_class":"PD-0332991, 125mg, 3 cycles","quality_score":null,"revenue":null,"mechanism":"PD-0332991, 125mg, 3 cycles"}],"offLabel":[],"totalMarketed":6,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT06248580","title":"Find HDV and Determine Its Status in Turkey","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Yaşar Bayındır, MD","has_results":false},{"nct_id":"NCT04525833","title":"Liver Disease and Other Systemic Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation","has_results":false},{"nct_id":"NCT03706742","title":"STOP HCC: Mailed HCV Treatment Outreach Program for HCC Prevention","phase":"NA","overall_status":"COMPLETED","enrollment_count":12386,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT05355662","title":"Prognosis Analysis of Elderly Donor Liver in Liver Transplantation","phase":"","overall_status":"COMPLETED","enrollment_count":11569,"lead_sponsor_name":"First Affiliated Hospital Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT06241326","title":"Immunotherapy for Hepatocellular Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":11000,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT07153783","title":"Interventional AI-Human Collaboration for Liver Tumor Diagnosis","phase":"NA","overall_status":"COMPLETED","enrollment_count":10333,"lead_sponsor_name":"Shengjing Hospital","has_results":false},{"nct_id":"NCT04442334","title":"The European NAFLD Registry","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Newcastle University","has_results":false},{"nct_id":"NCT06859840","title":"LEAF(Liver Tumor dEtection And classiFication AI)","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT03517332","title":"Circulating Tumor DNA Exposure in Peripheral Blood","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Quantgene Inc.","has_results":false},{"nct_id":"NCT06061328","title":"Project OASIS: Optimizing Approaches to Select Implementation Strategies","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":8020,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT07157085","title":"AI Multitask Model for HCC Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":7000,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03612726","title":"The Overall Survival of Patients With Unresectable HCC in Real-life","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Humanity & Health Medical Group Limited","has_results":false},{"nct_id":"NCT04348838","title":"Prospective Cohort of Patients With Hepatocellular Carcinoma in France","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Centre Hospitalier Universitaire, Amiens","has_results":false},{"nct_id":"NCT04371042","title":"PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT03047603","title":"Evaluation of Diagnostic Efficiency of PIVKA-II and Other Tumor Markers in HCC","phase":"","overall_status":"COMPLETED","enrollment_count":4005,"lead_sponsor_name":"Eastern Hepatobiliary Surgery Hospital","has_results":false},{"nct_id":"NCT04160897","title":"Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis","phase":"","overall_status":"UNKNOWN","enrollment_count":4000,"lead_sponsor_name":"Qing XIe","has_results":false},{"nct_id":"NCT05932719","title":"Multicentric Evaluation of COVID-19 Impact on Cancer Patients' Diagnostic and Management: Set-up of Indicators","phase":"","overall_status":"UNKNOWN","enrollment_count":4000,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT03702998","title":"Hepatocellular Carcinoma in HIV-infected Individuals in Asian Population","phase":"","overall_status":"COMPLETED","enrollment_count":3900,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT06062706","title":"Robotic vs. Laparoscopic vs. Open Living Donor Hepatectomy","phase":"","overall_status":"UNKNOWN","enrollment_count":3448,"lead_sponsor_name":"King Faisal Specialist Hospital & Research Center","has_results":false},{"nct_id":"NCT07368530","title":"Using Machine Learning to Identify Responders to TACE or HAIC for uHCC","phase":"","overall_status":"COMPLETED","enrollment_count":3000,"lead_sponsor_name":"First Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT04021056","title":"Observational Study on Patients With Hepatocellular Carcinoma (HCC)","phase":"","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT06776185","title":"Recurrence Patterns and Cost-Effectiveness of Surgical Approaches in Early-Stage Hepatocellular Carcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":3000,"lead_sponsor_name":"Chen Xiaoping","has_results":false},{"nct_id":"NCT03782207","title":"A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2756,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT00341705","title":"The Second Multicenter Hemophilia Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":2565,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03233360","title":"Hepatocellular Carcinoma Registry in Asia: The INSIGHT Registry","phase":"","overall_status":"COMPLETED","enrollment_count":2533,"lead_sponsor_name":"National Cancer Centre, Singapore","has_results":false},{"nct_id":"NCT05693519","title":"GastroIntestinal Cancer in Children and Adolescents","phase":"","overall_status":"UNKNOWN","enrollment_count":2500,"lead_sponsor_name":"Paul G. Kemps, MD","has_results":false},{"nct_id":"NCT05431621","title":"Establishment of Molecular Classification Models for Early Diagnosis of Digestive System Cancers","phase":"","overall_status":"COMPLETED","enrollment_count":2430,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT04681274","title":"Phenotyping Liver Cancer Registry","phase":"","overall_status":"COMPLETED","enrollment_count":2429,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05721300","title":"Study on Screening, Verification and Intervention of High-risk Patients With Liver Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":2215,"lead_sponsor_name":"Zhongshan Hospital (Xiamen), Fudan University","has_results":false},{"nct_id":"NCT03628651","title":"Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":2150,"lead_sponsor_name":"Exact Sciences Corporation","has_results":false},{"nct_id":"NCT06233708","title":"Association Between Pre-op Non-Selective Beta-Blockers and Hepatocellular Carcinoma Recurrence Post-Liver Transplant","phase":"","overall_status":"COMPLETED","enrollment_count":2092,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT05520801","title":"Primary Hepatobiliary Cancer Cohort of Central China","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT07156617","title":"A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Xuhua Duan","has_results":false},{"nct_id":"NCT05420922","title":"Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT07038863","title":"Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT06405321","title":"Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Guangxi Medical University","has_results":false},{"nct_id":"NCT06799468","title":"Validation of the TRAIN-AI for the Risk of HCC Recurrence After Liver Transplantation","phase":"","overall_status":"COMPLETED","enrollment_count":1769,"lead_sponsor_name":"European Hepatocellular Cancer Liver Transplant Group","has_results":false},{"nct_id":"NCT03232593","title":"A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)","phase":"","overall_status":"COMPLETED","enrollment_count":1758,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT05128123","title":"Influence of Social Determinants of Health on the Management of HCC in the French National Cohort Study CHIEF","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1600,"lead_sponsor_name":"University Hospital, Grenoble","has_results":false},{"nct_id":"NCT07091942","title":"Curative Therapy After Atezolizumab and Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":1600,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT03959800","title":"Molecular Basis of Pediatric Liver Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":1600,"lead_sponsor_name":"University of Pittsburgh","has_results":false},{"nct_id":"NCT05053412","title":"HELIO Liver Test Performance Study in China (HEPATIC)","phase":"","overall_status":"COMPLETED","enrollment_count":1556,"lead_sponsor_name":"Helio Genomics","has_results":false},{"nct_id":"NCT07444905","title":"Prospective Evaluation of a Locked Risk-Stratified Surveillance Strategy for Extrahepatic Metastasis in Hepatocellular Carcinoma","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1523,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT06647264","title":"A Multicenter Prospective Observational Study of Computer-aided Risk Perception and Prognosis Prediction in the Whole Process of Laparoscopic Hepatobiliary and Pancreatic Surgery","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1500,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT06179602","title":"Prospective Cohort Study on Thermal Ablation of Malignant Liver Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Leiden University Medical Center","has_results":false},{"nct_id":"NCT04161911","title":"A Study to Assess Overall Survival and Treatment Patterns for Advanced Liver Cancer Participants Who Received Nivolumab Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":1426,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT04414956","title":"Combining Biomarkers (AFP, AFP-L3, and PIVKA-II) and Image Tools for Early Detection of Hepatocellular Carcinoma","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1418,"lead_sponsor_name":"Korea University","has_results":false},{"nct_id":"NCT03298451","title":"Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1324,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT05176483","title":"Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1314,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT06624189","title":"Active Choice Clinical Decision Support (CDS): Hepatocellular Carcinoma (HCC) Screening in Patients With Cirrhosis","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1300,"lead_sponsor_name":"NYU Langone Health","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}